Core Viewpoint - The company, Jiaheng Jiahua, is forecasting a significant net loss for the year 2025, with expected losses ranging from 29 million to 39 million yuan for net profit attributable to shareholders, and from 32 million to 42 million yuan for net profit after deducting non-recurring gains and losses [1] Group 1: Financial Performance - The company anticipates a decline in net profit due to increased fixed operating costs, including depreciation and amortization from its wholly-owned subsidiary, Huzhou Jiaheng Industrial Co., Ltd., which has led to a decrease in sales gross margin compared to the previous year [1] - The company has experienced an increase in management expenses due to rising employee compensation and fixed asset depreciation to support the business development needs of Huzhou Jiaheng Industrial Co., Ltd. [1] - Financial expenses have also risen year-on-year, primarily due to an increase in bank borrowing and a reduction in interest capitalization during the reporting period [1]

Core Viewpoint - The company is actively expanding its product offerings in piperazine and its derivatives, focusing on applications in environmental chemicals and electronic chemicals [1] Environmental Chemicals - The company sees significant potential in its piperazine derivatives for the development of green and efficient solvents for carbon capture, particularly as carbon capture and storage (CCUS) projects are initiated in China [1] - The company is developing new green chemical products, including metal chelating agents and halogen-free flame retardants, which will provide better alternatives for water treatment and flame retardant industries [1] - The desulfurization and decarbonization agents developed by the company are emerging as high-performance environmental solvents with promising future prospects [1] Electronic Chemicals - The company has mastered several core technologies in the electronic chemicals sector, with products like N-hydroxyethyl piperazine and N,N-dimethyl propanamide demonstrating industry-leading performance [1] - These products meet the purity requirements for ultra-pure reagents in fine chemicals [1] - The technological route using piperazine as a raw material is expected to develop further with the advancement of domestic substitution and self-research in electronic chemicals [1]

主要是受市场环境及公司基于长远发展战略考量开发布局新牌号产品等因素影响，公司主营产品毛利率 阶段性承压；产品切换阶段需要对生产流程进行适应性调整，一定程度上制约了当期产量释放；子公司 浙江长鸿生物材料有限公司为提升装置生产效率而实施的停工技改周期较长，对产量造成阶段性影响； 同时，相关项目投资亦增加了公司的财务成本等因素综合影响所致。2025年度，面对严峻的行业形势， 公司管理层积极应对，基于公司行业地位与技术积淀，不断加强研发创新和市场开拓，深入挖潜降本增 效，营业收入增长明显。 格隆汇1月28日丨长鸿高科(605008.SH)公布，经财务部门初步测算，预计2025年年度实现归属于上市公 司股东的净利润150.00万元到200.00万元，同比减少97.88%到98.41%。预计2025年年度归属于上市公司 股东的扣除非经常性损益的净利润-1,500.00万元到-2,200.00万元，同比减少121.82%到132.00%。 ...

长鸿高科公告，预计2025年年度实现归属于上市公司股东的净利润150万元到200万元，与上年同期相 比，将减少9222.29万元到9272.29万元，同比减少97.88%到98.41%。预计2025年年度归属于上市公司股 东的扣除非经常性损益的净利润-1500万元到-2200万元，与上年同期相比，将减少8374.97万元到 9074.97万元，同比减少121.82%到132.00%。 ...

Core Viewpoint - Baomo Co., Ltd. is expected to report a significant decrease in net profit for the year 2025, while the net profit excluding non-recurring gains and losses is projected to increase substantially [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 25.91 million and 38.83 million yuan for 2025, representing a year-on-year decrease of 31.14% to 54.06% [1] - The net profit excluding non-recurring gains and losses is expected to be between 21.85 million and 32.75 million yuan, indicating a year-on-year increase of 422.23% to 682.74% [1] Business Operations - The increase in net profit excluding non-recurring gains and losses is primarily attributed to a rise in sales volume of the chemical business compared to the same period last year, leading to an increase in main business revenue [1] - The company's wholly-owned subsidiary, Chengdu Baomo Mining Co., Ltd., recovered receivables from equity transfer that were recognized in the same period last year, contributing to the financial performance [1]

证券之星消息，1月28日化学制品板块较上一交易日上涨1.38%，锦鸡股份领涨。当日上证指数报收于 4151.24，上涨0.27%。深证成指报收于14342.9，上涨0.09%。化学制品板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300798 | 锦鸡股份 | 9.58 | 20.05% | 81.59万 | | 7.45 Z | | 002440 | 国王股份 | 10.75 | 10.03% | 68.71万 | | 7.35亿 | | 600230 | 沧州大化 | 20.78 | 10.01% | 28.30万 | | 5.66亿 | | 600352 | 浙江龙盛 | 14.75 | 9.99% | 92.85万 | | 13.62亿 | | 002455 | 直川股份 | 7.93 | 9.99% | 63.07万 | | 4.98 亿 | | 603188 | 亚邦股份 | 5.31 | 9.94% | 25.29万 | | 1.33亿 | ...

Group 1 - The company announced that it has applied for a comprehensive credit limit of 100 million yuan from China Merchants Bank, with the credit period from January 27, 2026, to January 26, 2027 [1] - The wholly-owned subsidiary, Daierke, provides a joint liability guarantee for this credit limit and has signed an "Irrevocable Maximum Guarantee Agreement," which has been approved through Daierke's internal procedures [1] - As of the announcement date, the total external guarantees provided by the company amount to 46 million yuan, accounting for 1.31% of the most recent audited net assets, with no overdue external guarantees [1]

Core Viewpoint - The company, Jiu Ri New Materials, has indicated that approximately 12% of its total revenue comes from exports to the European Union, highlighting the significance of this market for its business operations [1] Group 1: Revenue Contribution - The revenue from the European market accounts for about 12% of the company's overall operating income [1] Group 2: Sales Strategy - The company has established an office in Europe and primarily conducts sales in this region through direct sales [1]

Group 1 - The core viewpoint of the article is that the company's export revenue to the European Union (EU) constitutes approximately 12% of its total operating income [1] - The company has established an office in Europe and primarily conducts sales in the EU through direct sales methods [1]

Group 1 - Precious metals and non-ferrous metals have surged again, with the A500 ETF (512050) rising by 0.40% as of 13:43, benefiting from strong performance in key sectors [1] - The A500 ETF has seen a year-to-date increase of over 33% as of yesterday, indicating robust market performance [1] - The Chinese yuan's central parity rate against the US dollar was adjusted up by 103 points to 6.9755, the highest since May 2023, with the largest increase since August [1] Group 2 - The A500 ETF (512050) offers investors a way to access core A-share assets with a low fee rate of only 0.2%, high liquidity, and a scale exceeding 40 billion yuan [2] - The ETF tracks the CSI A500 Index, employing a dual strategy of industry-balanced allocation and leading stock selection, covering all 35 sub-sectors [2] - Compared to the CSI 300, the A500 ETF is overweight in sectors such as AI industry chain, pharmaceutical biology, and new energy power equipment, showcasing a natural "barbell" investment strategy [2]